CSPHF (CStone Pharmaceuticals) Common Stock: $0.14 Mil (As of Dec. 2025)


CSPHF CStone Pharmaceuticals CSPHF
47 GF Score
Price $0.59
GF Value $0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Common Stock?

CStone Pharmaceuticals CSPHF -14.46% 47 Common Stock is $0.14 Mil as of Dec. 2025. GuruFocus rates CSPHF with a GF Score™ of 47/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 7 warning signs investors should review.

CStone Pharmaceuticals's quarterly common stock increased from Dec. 2024 ($0.12 Mil) to Jun. 2025 ($0.13 Mil) and increased from Jun. 2025 ($0.13 Mil) to Dec. 2025 ($0.14 Mil).

CStone Pharmaceuticals's annual common stock declined from Dec. 2023 ($0.12 Mil) to Dec. 2024 ($0.12 Mil) but then increased from Dec. 2024 ($0.12 Mil) to Dec. 2025 ($0.14 Mil).

CStone Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals Common Stock Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.12 0.12 0.12 0.14

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.12 0.13 0.14
CSPHF
47GF Score
CStone Pharmaceuticals CSPHF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CStone Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.14 Mil mean?
CStone Pharmaceuticals (CSPHF) has a Common Stock of $0.14 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' Common Stock too high?
CStone Pharmaceuticals' current Common Stock is $0.14 Mil. Overall, CStone Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Common Stock compare to VRTX and REGN?
CStone Pharmaceuticals' Common Stock of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current Common Stock is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $0.59 — trading 395.4% above its estimated fair value. The current Common Stock is $0.14 Mil. CStone Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Common Stock is $0.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.59 is trading 395.4% above its estimated GF Value™ of $0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • Common Stock: $0.14 Mil
  • GF Value™: $0.12 vs. price of $0.59 (395.4% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
47GF Score

Get the complete analysis for CSPHF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.12
GF Value